Publications by authors named "Ryan A Lafferty"

Claim this Profile
N
Novel enzyme-resistant pancreatic polypeptide analogs evoke pancreatic beta-cell rest, enhance islet cell turnover, and inhibit food intake in mice.
Wuyun Zhu, Neil Tanday, Ryan A Lafferty, Peter R Flatt, Nigel Irwin

Biofactors· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?
Ryan A Lafferty, Peter R Flatt, Nigel Irwin

Peptides· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?
Ryan A Lafferty, Peter R Flatt, Victor A Gault, Nigel Irwin

J Endocrinol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy.
Ryan A Lafferty, Peter R Flatt, Nigel Irwin

Expert Opin Pharmacother· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antidiabetic actions of GPR55 agonist Abn-CBD and sitagliptin in obese-diabetic high fat fed mice.
Andrew G McCloskey, Michael G Miskelly, Ryan A Lafferty, Peter R Flatt, Aine M McKillop

Biochem Pharmacol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists.
Neil Tanday, Ryan A Lafferty, Peter R Flatt, Nigel Irwin

Diabetes Obes Metab· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice.
Ryan A Lafferty, Laura M McShane, Zara J Franklin, Peter R Flatt, Finbarr P M O'Harte

J Endocrinol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of artemether on pancreatic islet morphology, islet cell turnover and α-cell transdifferentiation in insulin-deficient GluCreERT2;ROSA26-eYFP diabetic mice.
Dipak Sarnobat, Ryan A Lafferty, R Charlotte Moffett, Andrei I Tarasov, Peter R Flatt

J Pharm Pharmacol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice.
Zara J Franklin, Ryan A Lafferty, Peter R Flatt, Laura M McShane, Finbarr P M O'Harte

Biochimie· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ac3IV, a V1a and V1b receptor selective vasopressin analogue, protects against hydrocortisone-induced changes in pancreatic islet cell lineage.
Shruti Mohan, Ryan A Lafferty, Peter R Flatt, R Charlotte Moffett, Nigel Irwin

Peptides· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice.
Ryan A Lafferty, Neil Tanday, R Charlotte Moffett, Frank Reimann, Fiona M Gribble

Front Endocrinol (Lausanne)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
Neil Tanday, Andrew English, Ryan A Lafferty, Peter R Flatt, Nigel Irwin

Front Endocrinol (Lausanne)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proglucagon-Derived Peptides as Therapeutics.
Ryan A Lafferty, Finbarr P M O'Harte, Nigel Irwin, Victor A Gault, Peter R Flatt

Front Endocrinol (Lausanne)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physicochemical, Nutritional and In Vitro Antidiabetic Characterisation of Blue Whiting () Protein Hydrolysates.
Pádraigín A Harnedy-Rothwell, Neda Khatib, Shaun Sharkey, Ryan A Lafferty, Snehal Gite

Mar Drugs· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes.
Ryan A Lafferty, Peter R Flatt, Nigel Irwin

Curr Opin Endocrinol Diabetes Obes· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activity.
Ryan A Lafferty, Neil Tanday, Peter R Flatt, Nigel Irwin

Metabolism· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes induction.
Ryan A Lafferty, Neil Tanday, Peter R Flatt, Nigel Irwin

Biochim Biophys Acta Gen Subj· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide YY (1-36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β-cell function, growth and survival.
Ryan A Lafferty, Neil Tanday, Andrew McCloskey, Pradeep Bompada, Yang De Marinis

Diabetes Obes Metab· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of 2 Novel PYY(1-36) Analogues, (PLP)PYY(1-36) and PYY(1-36)(LysPAL), on Pancreatic Beta-Cell Function, Growth, and Survival.
Ryan A Lafferty, Victor A Gault, Peter R Flatt, Nigel Irwin

Clin Med Insights Endocrinol Diabetes· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging therapeutic potential for peptide YY for obesity-diabetes.
Ryan A Lafferty, Peter R Flatt, Nigel Irwin

Peptides· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Galleria mellonella as a novel in vivo model for assessment of the toxicity of 1-alkyl-3-methylimidazolium chloride ionic liquids.
Julianne Megaw, Thomas P Thompson, Ryan A Lafferty, Brendan F Gilmore

Chemosphere· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis